Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2012-03-13

FDA Approved: ZYRTEC HIVES — Supplemental Application (Kenvue Brands LLC)

View source ↗

Summary

FDA approved a supplemental application for ZYRTEC HIVES to expand cetirizine hydrochloride labeling to include treatment of hives (urticaria).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYRTEC HIVES (cetirizine hydrochloride)

Snippet

SUPPL AP for ZYRTEC HIVES (CETIRIZINE HYDROCHLORIDE)